NASDAQ:SGMT
Sagimet Biosciences Inc.
Sagimet Biosciences Inc. reported net income of −$51.0M in fiscal 2025. The diluted share count rose 3.2%.Summary generated from Sagimet Biosciences Inc.'s SEC filings. Latest annual report filed Mar 11, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−38.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+3.2%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | 2 | n/a | n/a |
| Operating income | −31 | −31 | −54 | −57 |
| Net income | −30 | −28 | −46 | −51 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Oct 1, 2026 - 8-KRegulation FD disclosure
Sep 30, 2026 - 4Insider transaction report
Aug 17, 2026 - 8-KOther events
Aug 13, 2026 - 4Insider transaction report
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KRegulation FD disclosure
Jul 21, 2026